Is It Possible to Differentiate Chronic Kidney Disease and Preeclampsia by means of New and Old Biomarkers? A Prospective Study

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Rolfo, Alessandro ^a   Attini, Rossella ^a   Tavassoli, Elisabetta ^a   Vigotti Neve, Federica ^a   Nigra, Marco ^b   Cicilano, Matteo ^b   Nuzzo, Anna Maria ^a   Giuffrida, Domenica ^a   Biolcati, Marilisa ^a   Nichelatti, Michele ^c   Gaglioti, Pietro ^a   Todros, Tullia ^a   Piccoli, Giorgina Barbara ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b S GIOVANNI BOSCO HOSPITAL   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; PGF PROTEIN, HUMAN; PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DOPPLER FLOWMETRY; FEMALE; GESTATIONAL AGE; HUMAN; IMMUNOASSAY; IMMUNOASSAY ANALYZER; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PREECLAMPSIA; PREMATURE LABOR; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; UMBILICAL ARTERY; UTERINE ARTERY; BLOOD; CHRONIC KIDNEY FAILURE; DIAGNOSTIC IMAGING; ECHOGRAPHY; EVALUATION STUDY; MIDDLE AGED; PREGNANCY;

ADULT; BIOMARKERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MIDDLE AGED; PLACENTA GROWTH FACTOR; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; RENAL INSUFFICIENCY, CHRONIC; ULTRASONOGRAPHY; UTERINE ARTERY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84945293374     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/127083     Document Type: Article

References (39)

1. S. Lisonkova and K. S. Joseph, "Incidence of preeclampsia: risk factors and outcomes associated with early-versus late-onset disease," American Journal of Obstetrics & Gynecology, vol. 209, no. 6, pp. 544.e1-544.e12, 2013.
2. N. Arulkumaran and L. Lightstone, "Severe pre-eclampsia and hypertensive crises," Best Practice and Research: Clinical Obstetrics and Gynaecology, vol. 27, no. 6, pp. 877-884, 2013.
3. E. Ciantar and J. J.Walker, "Pre-eclampsia, severe pre-eclampsia and hemolysis, elevated liver enzymes and low platelets syndrome: what is new?" Women's Health, vol. 7, no. 5, pp. 555-569, 2011.
4. Z. Al-Safi, A. N. Imudia, L. C. Filetti, D. T. Hobson, R. O. Bahado-Singh, and A. O. Awonuga, "Delayed postpartum preeclampsia and eclampsia: demographics, clinical course, and complications," Obstetrics & Gynecology, vol. 118, no. 5,pp. 1102-1107, 2011.
5. 2015, http://www.kidney.org/.
6. D. Williams and J. Davison, "Chronic kidney disease in pregnancy," British Medical Journal, vol. 336, no. 7637, pp. 211-215, 2008.
7. D. Berks, E. A. P. Steegers, M.Molas, andW. Visser, "Resolution of hypertension and proteinuria after preeclampsia," Obstetrics and Gynecology, vol. 114, no. 6, pp. 1307-1314, 2009.
8. K. Duckitt and D. Harrington, "Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies," British Medical Journal, vol. 330, no. 7491, pp. 565-567, 2005.
9. Publications Committee, Society for Maternal-Fetal Medicine, and B. M. Sibai, "Evaluation and management of severe preeclampsia before 34 weeks' gestation," American Journal of Obstetrics and Gynecology, vol. 205, no. 3, pp. 191-198, 2011.
10. Y. Mikami, K. Takagi, Y. Itaya et al., "Post-partum recovery course in patients with gestational hypertension and preeclampsia," Journal of Obstetrics and Gynaecology Research, vol. 40, no. 4, pp. 919-925, 2014.
11. http://www.acog.org/Resources And Publications/Task Force and Work Group Reports/Hypertension in Pregnancy.
12. B. Jimand S. Hou, "Pregnancy and kidney disease-the miracle continues against all odds," Advances in Chronic Kidney Disease, vol. 20, no. 3, pp. 206-208, 2013.
13. V. D. Garovic, S. J.Wagner, S.T.Turner et al., "Urinarypodocyte excretion as a marker for preeclampsia," American Journal of Obstetrics & Gynecology, vol. 196, no. 4, pp. 320.e1-320.e7, 2007.
14. W. M.White, A. T. Garrett, I. M. Craici et al., "Persistent urinary podocyte loss following preeclampsia may reflect subclinical renal injury," PLoS ONE, vol. 9, no. 3,Article ID e92693, 2014.
15. T. C. Allbutt, "Albuminuria in pregnancy," The Lancet, vol. 149, no. 3835, pp. 579-582, 1897.
16. G. B. Piccoli, P. Gaglioti, R. Attini et al., "Pre-eclampsia or chronic kidney disease? the flow hypothesis," Nephrology Dialysis Transplantation, vol. 28, no. 5, pp. 1199-1206, 2013.
17. A. Rolfo, R. Attini, A. M. Nuzzo et al., "Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers," Kidney International, vol. 83, no. 1, pp. 177-181, 2013.
18. M. Parra, R. Rodrigo, P. Barja et al., "Screening test for preeclampsia through assessment of uteroplacental blood flow and biochemical markers of oxidative stress and endothelial dysfunction," American Journal of Obstetrics & Gynecology, vol. 193, no. 4, pp. 1486-1491, 2005.
19. A. T. Papageorghiou and N. Roberts, "Uterine artery Doppler screening for adverse pregnancy outcome," Current Opinion in Obstetrics and Gynecology, vol. 17, no. 6, pp. 584-590, 2005.
20. R. Gaillard, L. R. Arends, E. A. P. Steegers, A.Hofman, andV.W. V. Jaddoe, "Second-and third-trimester placental hemodynamics and the risks of pregnancy complications," American Journal of Epidemiology, vol. 177, no. 8, pp. 743-754, 2013.
21. S. Rana, C. E. Powe, S. Salahuddin et al., "Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia," Circulation, vol. 125, no. 7, pp. 911-919, 2012.
22. T. A. M. Simas, S. L. Crawford, M. J. Solitro, S. C. Frost, B. A. Meyer, and S. E. Maynard, "Angiogenic factors for the prediction of preeclampsia in high-risk women," American Journal of Obstetrics & Gynecology, vol. 197, no. 3, pp. 244.e1-244.e8, 2007.
23. K. E. Duhig, L. C. Chappell, and A. H. Shennan, "How placental growth factor detection might improve diagnosis and management of pre-eclampsia," Expert Review of Molecular Diagnostics, vol. 14, no. 4, pp. 403-406, 2014.
24. S. Verlohren, I. Herraiz, O. Lapaire et al., "The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients," American Journal of Obstetrics & Gynecology, vol. 206, no. 1, pp. 58.e1-58.e8, 2012.
25. C. E. Kleinrouweler, M. M. J. Wiegerinck, C. Ris-Stalpers et al., "Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis," BJOG, vol. 119, no. 7, pp. 778-787, 2012.
26. R.W. Powers, A. Jeyabalan, R. G. Clifton et al., "Soluble fmslike tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies," PLoS ONE, vol. 5, no. 10, Article IDe13263, 2010.
27. T. D.Metz, A. A. Allshouse, A. G. Euser, and K. D. Heyborne, "Preeclampsia in high risk women is characterized by risk group-specific abnormalities in serum biomarkers," American Journal of Obstetrics & Gynecology, vol. 211, no. 5, pp. 512.e1-512.e6, 2014.
28. P. I.Gómez-Arriaga, I.Herraiz, E. A. López-Jiménez, E.Gómez-Montes, B. Denk, and A. Galindo, "Uterine artery Doppler and sFlt-1/PlGF ratio: usefulness in diagnosis of pre-eclampsia," Ultrasound in Obstetrics & Gynecology, vol. 41, no. 5, pp. 530-537, 2013.
29. J.-C. Forest, S. Thériault, J. Massé, E. Bujold, and Y. Giguère, "Soluble Fms-like tyrosine kinase-1 to placental growth factor ratio in mid-pregnancy as a predictor of preterm preeclampsia in asymptomatic pregnant women," Clinical Chemistry and Laboratory Medicine, vol. 52, no. 8, pp. 1169-1178, 2014.
30. G. B. Piccoli, F. Fassio, R. Attini et al., "Pregnancy in CKD: whom should we follow and why?" Nephrology Dialysis Transplantation, vol. 27, supplement 3, pp. iii111-iii118, 2012.
31. G. B. Piccoli, R. Attini, E. Vasario et al., "Pregnancy and chronic kidney disease: a challenge in all CKD stages," Clinical Journal of the American Society of Nephrology, vol. 5, no. 5, pp. 844-855, 2010.
32. S. Verlohren, A. Galindo, D. Schlembach et al., "An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia," American Journal of Obstetrics & Gynecology, vol. 202, no. 2, pp. 161.e1-161.e11, 2010.
33. M. A. G. Coleman, L. M. E. McCowan, and R. A. North, "Midtrimester uterine artery Doppler screening as a predictor of adverse pregnancy outcome in high-risk women," Ultrasound in Obstetrics and Gynecology, vol. 15, no. 1, pp. 7-12, 2000.
34. C. Guiot, P. Gaglioti, M. Oberto, E. Piccoli, R. Rosato, and T. Todros, "Is three-dimensional power Doppler ultrasound useful in the assessment of placental perfusion in normal and growth-restricted pregnancies?" Ultrasound in Obstetrics and Gynecology, vol. 31, no. 2, pp. 171-176, 2008.
35. June 2014, http://www.inescharts.com/.
36. S. E. Maynard, S. L. Crawford, S. Bathgate et al., "Gestational angiogenic biomarker patterns in high risk preeclampsia groups," American Journal of Obstetrics and Gynecology, vol. 209, no. 1, pp. 53.e1-53.e9, 2013.
37. C. M. Koopmans, D. Bijlenga, H. Groen et al., "Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial," The Lancet, vol. 374, no. 9694, pp. 979-988, 2009.
38. 2015, http://www.snlg-iss.it/cms/files/LG Gravidanza.pdf.
39. 2015, http://www.nice.org.uk/guidance/cg62/resources/guidance-antenatal-care-pdf.